Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

BACKGROUND: Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jaiswal, Bijay S., Janakiraman, Vasantharajan, Kljavin, Noelyn M., Eastham-Anderson, Jeffrey, Cupp, James E., Liang, Yuxin, Davis, David P., Hoeflich, Klaus P., Seshagiri, Somasekar
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2009
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2683562/
https://ncbi.nlm.nih.gov/pubmed/19492075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0005717
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items